加载中
NASDAQHealthcareDrug Manufacturers - General
最新数据
US$11.53
−US$0.50 · -4.16%
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
前收盘价
US$11.53
−US$0.50 · -4.16%
盘后
US$11.53
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
日内区间
当前US$11.53
52周区间
当前US$11.53
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
48
合理估值
情绪
52
多空交织
风险
43
风险偏高
动量
40
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
日内区间
当前US$11.53
52周区间
当前US$11.53
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.14亿 USD | 2.29亿 USD | 3.07亿 USD | 3.69亿 USD | 5.83亿 USD |
| 销货成本 | 9277.8万 USD | 1.47亿 USD | 1.41亿 USD | 1.27亿 USD | 1.21亿 USD |
| 毛利 | 1.21亿 USD | 8138.2万 USD | 1.66亿 USD | 2.42亿 USD | 4.62亿 USD |
| 研究与开发 | 1980.6万 USD | 2086.9万 USD | 2221.9万 USD | 3041.1万 USD | 2930.7万 USD |
| 销售、一般及管理费用 | 1.15亿 USD | 1.52亿 USD | 2亿 USD | 3.04亿 USD | 4.08亿 USD |
| 营业费用 | 1.35亿 USD | 1.73亿 USD | 2.22亿 USD | 3.48亿 USD | 4.51亿 USD |
| 利息收入 | 1085.3万 USD | 1340.3万 USD | 1186.3万 USD | 281.9万 USD | 122万 USD |
| 利息支出 | 7000 USD | 7000 USD | 8000 USD | 1.5万 USD | 12.9万 USD |
| 折旧和摊销 | 302.8万 USD | 291.5万 USD | 296.5万 USD | 309.6万 USD | 285.7万 USD |
| 营业利润 | −1394.1万 USD | −9179.7万 USD | −5661.6万 USD | −1.06亿 USD | 1050.2万 USD |
| 净利润 | −3879.8万 USD | −8218.3万 USD | −5911.2万 USD | −1.06亿 USD | 772.9万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
